Studies have also demonstrated that small molecules such as PD-1 (programmed cell death protein)/PD-L1 (programmed death ligand-1) conjugating peptides have drawn a lot of interest in cancer immunotherapy because of their potential to disrupt PD-1/PD-L1 interactions [84]. Here, CD274 is linked to cancer.